Lastly, subependymomas are considered slow-growing WHO grade 1 tumors, presenting with CSF obstruction if intracranial or myelopathy/radiculopathy if spinal, and with tumorigenesis likely driven by loss of chromosome 6q and alterations in topoisomerase and p-STAT3/HIF-1α inhibitors, which represent viable molecular therapeutic targets (81). This evidence concerns the gene HIF1A and subependymoma.